Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer

Cisplatin-based chemotherapy has been the standard of care for patients with locally advanced or metastatic urothelial cancer (la/mUC). Enfortumab vedotin, an antibody-drug conjugate directed to Nectin-4, and pembrolizumab, an immune checkpoint inhibitor, are two therapies that have individually pro...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Blaine Brower, Asia McCoy, Hiba Ahmad, Cheryl Eitman, I. Alex Bowman, Jennifer Rembisz, Matthew I. Milowsky
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Subjects:	enfortumab vedotin pembrolizumab urothelial cancer anticancer therapy adverse events immune-related adverse events
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1326715/full